This market resolves to “Yes” if, by December 31, 2026, at 11:59 PM ET, the U.S. Food and Drug Administration (FDA) grants approval, emergency use authorization (EUA), or licensure for any vaccine specifically indicated for prevention of hantavirus infection in humans. Otherwise, this market resolves to “No.”

For purposes of this market, “hantavirus” includes hantavirus pulmonary syndrome (HPS) and other human hantavirus diseases. Approval or authorization in countries outside the United States alone will not qualify.

Primary resolution sources will include official FDA announcements, FDA databases, and company press releases.